Human Pharmaceuticals

Our experience, results and projects are displayed geographically. Please scroll down to your geographical area of interest to see details.

North America

• Available for licensing – Biosimilars, Anti-Osteoporosis, Hormone therapy
• Available for licensing – Biosimilar, Oncology
• Available for licensing – Anti-Diabetics
• ANDA received, launch pending – Anti-Osteoporosis
• ANDA awaited – Anti-Osteoporosis
• ANDA awaited – Gastroesophageal Reflux Disease
• In-development – Anti-Diabetic, peptide
• In-development – Anti-Edema, peptide

Would you like more information on how Cetalus could market your winning products to 2000 top companies in 50 countries? Or secure for you winning products?

Central and South America

• Available for licensing – Biosimilars, Anti-Osteoporosis, Hormone therapy
• Available for licensing – Biosimilar, Oncology
• Available for licensing – Anti-Cardiovascular, Anti-Diabetes, Anti-Fungals, Anti-Inflammatories, Anti-Malarials, Anti-Migraine, Dermatologicals, Opthalmic
• Out-licensed Cardiovascular generic to leap frog innovator product
• Out-licensing Oncology business to achieve market-share leadership
• Successful launch q2, 2016 – Anti-Alzheimer’s
• Approval awaited – Multiple Sclerosis
• Unique market-based pricing strategy
• Out-licensing Anti-Diabetic drug for market-share leadership

Would you like more information on how Cetalus could market your winning products to 2000 top companies in 50 countries? Or secure for you winning products?

Asia

• Available for licensing – Biosimilars, Anti-Osteoporosis, Hormone therapy
• Turn-around of loss making Human Pharmaceuticals business
• Industry-first segmentation, portfolio prioritization, promotion
• Re-positioning of cough, colds product to achieve leadership
• Re-launch anti-inflammatories for successful commercialization
• Addition of user group to reverse sales decline of colds medication
• Out-licensing Anti-Diabetic drug for market-share leadership

Would you like more information on how Cetalus could market your winning products to 2000 top companies in 50 countries? Or secure for you winning products?

Europe, Africa

• Available for licensing – Biosimilars, Anti-Osteoporosis, Hormone therapy
• Out-licensing Anti-Diabetic drug for market-share leadership

Would you like more information on how Cetalus could market your winning products to 2000 top companies in 50 countries? Or secure for you winning products?